GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Regentis Biomaterials Corp (NAS:RGNT) » Definitions » Piotroski F-Score

Regentis Biomaterials (Regentis Biomaterials) Piotroski F-Score : 0 (As of Jun. 18, 2024)


View and export this data going back to 2050. Start your Free Trial

What is Regentis Biomaterials Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Regentis Biomaterials has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Regentis Biomaterials's Piotroski F-Score or its related term are showing as below:


Regentis Biomaterials Piotroski F-Score Historical Data

The historical data trend for Regentis Biomaterials's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regentis Biomaterials Piotroski F-Score Chart

Regentis Biomaterials Annual Data
Trend Dec20 Dec21 Dec22
Piotroski F-Score
- - -

Regentis Biomaterials Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Piotroski F-Score Get a 7-Day Free Trial - - - - -

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec22) TTM:Last Year (Dec21) TTM:
Net Income was $-1.38 Mil.
Cash Flow from Operations was $-1.50 Mil.
Revenue was $0.00 Mil.
Gross Profit was $0.00 Mil.
Average Total Assets from the begining of this year (Dec21)
to the end of this year (Dec22) was (3.115 + 1.717) / 2 = $2.416 Mil.
Total Assets at the begining of this year (Dec21) was $3.12 Mil.
Long-Term Debt & Capital Lease Obligation was $6.47 Mil.
Total Current Assets was $1.72 Mil.
Total Current Liabilities was $2.41 Mil.
Net Income was $-5.14 Mil.

Revenue was $0.00 Mil.
Gross Profit was $0.00 Mil.
Average Total Assets from the begining of last year (Dec20)
to the end of last year (Dec21) was (1.386 + 3.115) / 2 = $2.2505 Mil.
Total Assets at the begining of last year (Dec20) was $1.39 Mil.
Long-Term Debt & Capital Lease Obligation was $6.08 Mil.
Total Current Assets was $3.12 Mil.
Total Current Liabilities was $2.72 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Regentis Biomaterials's current Net Income (TTM) was -1.38. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Regentis Biomaterials's current Cash Flow from Operations (TTM) was -1.50. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec21)
=-1.383/3.115
=-0.44398074

ROA (Last Year)=Net Income/Total Assets (Dec20)
=-5.142/1.386
=-3.70995671

Regentis Biomaterials's return on assets of this year was -0.44398074. Regentis Biomaterials's return on assets of last year was -3.70995671. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Regentis Biomaterials's current Net Income (TTM) was -1.38. Regentis Biomaterials's current Cash Flow from Operations (TTM) was -1.50. ==> -1.50 <= -1.38 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=6.472/2.416
=2.67880795

Gearing (Last Year: Dec21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec20 to Dec21
=6.075/2.2505
=2.69940013

Regentis Biomaterials's gearing of this year was 2.67880795. Regentis Biomaterials's gearing of last year was 2.69940013. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec22)=Total Current Assets/Total Current Liabilities
=1.717/2.411
=0.71215263

Current Ratio (Last Year: Dec21)=Total Current Assets/Total Current Liabilities
=3.115/2.723
=1.14395887

Regentis Biomaterials's current ratio of this year was 0.71215263. Regentis Biomaterials's current ratio of last year was 1.14395887. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Regentis Biomaterials's number of shares in issue this year was 11.561. Regentis Biomaterials's number of shares in issue last year was 11.561. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Regentis Biomaterials's gross margin of this year was . Regentis Biomaterials's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec21)
=0/3.115
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec20)
=0/1.386
=0

Regentis Biomaterials's asset turnover of this year was 0. Regentis Biomaterials's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+1+0+1+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Regentis Biomaterials has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Regentis Biomaterials  (NAS:RGNT) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Regentis Biomaterials Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Regentis Biomaterials's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Regentis Biomaterials (Regentis Biomaterials) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
12 Ha’ilan Street, P.O. Box 260, Northern Industrial Zone, Or-Akiva, ISR, 306000
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

Regentis Biomaterials (Regentis Biomaterials) Headlines

No Headlines